The visceral fat area to leg muscle mass ratio is significantly associated with the risk of hyperuricemia among women: a cross-sectional study

Xiao-He Wang, Wei-Ran Jiang, Min-Ying Zhang, Ying-Xin Shi, Yun-Ping Ji, Chun-Jun Li* and Jing-Na Lin*

Abstract

Background: A significant positive association was found in previous studies among obesity, visceral fat accumulation, and hyperuricemia. The purpose of this study was to explore the association between the ratio of visceral fat area to leg muscle mass (VFA-to-LMM) and hyperuricemia, and verify the role of gender differences in the association.

Methods: A total of 3393 (43.3% are men) participants from Tianjin Union Medical Center-Health Management Center were recruited for this cross-sectional study. The VFA-to-LMM ratio was used as the independent variable. Hyperuricemia, a serum uric acid level ≥ 416 μmol/L in men and in menopausal women and ≥ 357 μmol/L in premenopausal women, was used as the dependent variable. Multiple logistic regression analysis was used to estimate the odds ratio and the 95% confidence interval between the VFA-to-LMM ratio and hyperuricemia.

Results: The overall prevalence of hyperuricemia was 14.8% (8.9% in women, and 22.5% in men). After adjustment by age, smoking status (for males), menopause status (for females), drinking status, exercise frequency, blood pressure, alanine aminotransferase, fasting plasma glucose, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, creatinine, and history of diseases, a strong positive association was found between the VFA-to-LMM ratio and hyperuricemia in both men (4th vs. 1st quartile 1.60, 95%CI: 1.03–2.49) and women (4th vs. 1st quartile 5.22, 95%CI: 2.44–12.56). After additional adjustment by BMI, there was still a significant positive association in women (4th vs. 1st quartile 2.57, 95%CI: 1.06–6.77). The results of subgroup analysis showed that premenopausal women (4th vs. 1st quartile OR: 3.61) have a higher risk of hyperuricemia than postmenopausal women (4th vs. 1st quartile OR: 1.94) with the increase of the VFA-to-LMM ratio. Besides, the interaction analysis results showed the highest risk of hyperuricemia when VFA and LMM were both in the highest quantile (OR: 11.50; 95% CI: 4.86–31.98).

(Continued on next page)
Introduction
According to the National Health and Nutrition Examination Survey [1], the prevalence rates of hyperuricemia were 20.2% for men and 20.0% for women during 2007–2016, and the rates did not show any decline in the decade. Compared with the high prevalence of hyperuricemia in the USA, although China has a relatively low prevalence of hyperuricemia (19.4% in men and 7.9% in women) [2], it is still rising according to the latest data [3]. Hyperuricemia, a metabolic disease, is closely related to the inflammatory response and the disorder of glucose and lipid metabolism [4], which plays an important role in the formation of metabolic syndrome [5]. In addition, hyperuricemia, inflammation, and oxidative stress can accelerate the process of endothelial dysfunction, which is the pathophysiological basis of metabolic syndrome [6]. Moreover, hyperuricemia has also been shown to be significantly associated with lifestyle-related chronic diseases, such as hypertension, diabetes [7], non-alcoholic fatty liver disease (NAFLD) [8], and cancer. In addition, a meta-analysis based on cohort studies also confirmed that hyperuricemia was associated with high cancer incidence and mortality [9].

Considering the serious health outcomes caused by hyperuricemia, plenty of researchers have started to study its risk factors. A large population-based study confirmed that four modifiable risk factors, including the body mass index (BMI), alcohol use, diuretic use, and Dietary Approaches to Stop Hypertension diet, are independently associated with the development of hyperuricemia [10]. Among these modifiable risk factors, BMI is a comprehensive indicator that could indirectly reflect the overall condition of diet, physical activity, and metabolism. There is a complex correlation between obesity and hyperuricemia. The former can cause hyperuricemia by increasing uric acid synthesis and inhibiting its excretion, and (in turn) increased uric acid levels can promote the development of obesity by accelerating body fat accumulation (especially visceral fat) [11]. However, BMI fails to reflect the metabolic differences between men and women, such as fat distribution and skeletal muscle mass (SMM). In fact, studies have proved that there was a positive association between visceral fat and hyperuricemia [12–14], and a significant inverse association between serum uric acid (SUA) levels and SMM [15, 16]. Furthermore, studies have shown that leg composition was associated with some metabolic diseases [17, 18].

Methods
Participants
The target population for the study was those who visited Tianjin Union Medical Center-Health Management Center for an annual physical examination from September 2019 to December 2019.

Before body composition examination, participants were interviewed and those who had recently taken specific drugs (diuretics, hypoglycemic agents, aspirin, vitamin C, etc.) were excluded because these drugs might affect uric acid metabolism. A total of 4084 eligible adults were enrolled in the study, among which 602 were excluded because they did not provide complete information, including physical examinations, biochemical analysis, questionnaires, and body composition, 9 were excluded because they had a history of cancer, and 52 were excluded because they were above 85 years old, as the association between body composition and hyperuricemia due to stability of physiological indicators or serious declination of health status might be affected. Besides, the participants (n = 28) who have extreme values in the measurement indicators were also excluded. Finally, 3393 (83% of those eligible) subjects had
valid body composition data and covariate information required for the cross-sectional study (Fig. 1).

**Measurement of body composition**
Body composition was measured by multielectrode bio-electrical impedance analyzer (Inbody 770, Biospace Inc., Korea). According to the manufacturer’s guidelines, subjects were required to fast overnight and wipe the bottom of their feet with clean water before taking measurements. They were instructed to stand barefoot on the base components with light clothing and grasp the handles of the instrument to ensure full contact with a total of 8 electrodes. Then they were asked to slightly abduct their arms and maintain the posture during the assessment. The entire measurement process took about 3–4 min, and the data were automatically saved in the computer after the measurement was completed. Based on the purpose of this study, the VFA-to-LMM ratio was selected as the independent variable.

**Covariables**
Weight and height were measured by an automatic height and weight instrument (DST-600, Dongguan, China), and participants were required to stay barefooted with light clothing during the measurement. BMI was calculated as weight in kilograms divided by the square of height in meters. All measurements are carried out in strict accordance with the national standards.

Blood pressure was measured using an automatic electronic blood pressure monitor (AC-05C, Ling Qian, China) after a 10-min rest. Each person was measured three times and the average value was taken. Hypertension is defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic...
blood pressure (DBP) ≥ 90 mmHg or with a history of hypertension. Ultrasound liver examination was performed by an experienced ultrasound physician using an ultrasound diagnosis system (Phoenix, Philips and Neusoft Medical Systems Co., Ltd., China). The diagnosis of NAFLD was based on imaging diagnostic criteria [24]: (1) the near-field echo of the liver is diffusely enhanced (bright liver), and liver echogenicity is greater than that of kidney or spleen; (2) vascular blurring; and (3) deep attenuation of ultrasound signal. Blood biochemical analysis was performed using an automatic biochemical analyzer (TBA-120FR, Toshiba, Japan), and participants were required to fast overnight (only allowed to drink water), and venous blood was collected in a fasting state. The main indicators of blood biochemical analysis include alanine aminotransferase (ALT), fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C) cholesterol, and serum uric acid. Diabetes is defined as FPG ≥ 7.0 mmol/L or with a history of diabetes. Dyslipidemia is defined as TC ≥ 6.2 mmol/L or TG ≥ 2.3 mmol/L or LDL-C ≥ 4.1 mmol/L or HDL-C < 1.0 mmol/L according to the Chinese Guidelines for the Management of Dyslipidemia in Adults (2016) [25]. Hyperuricemia is defined as a serum uric acid level ≥ 416 μmol/L in men and menopausal women, and ≥ 357 μmol/L in premenopausal women.

The socio-demographic variables, such as gender, age, and menopause status, were collected through questionnaires. Information on lifestyles, including exercise frequency (“never,” “occasional,” and “regularly”), smoking status (“smoker,” “Ex-smoker,” and “Non-smoker”), drinking status (“drinker,” and “ex-drinker,” and “non-drinker”), and sedentary status (> 6 h/day), was also obtained in questionnaires. As for the history of diseases (including diabetes, hypertension, coronary heart disease, and cancer), participants were required to answer a “yes” or “no”.

**Statistical analysis**

The characteristics of participants were presented as the means ± standard deviation or the median (interquartile range) for continuous variables and percentages for categorical variables. Statistical differences between groups were examined through analysis of variance for continuous variables and Chi-square test for categorical variables. Multiple logistic regression analysis was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) between the VFA-to-LMM ratio and hyperuricemia. For further analysis, we fitted four models and performed a quartile conversion of the independent variable. Model 1 was adjusted by age and model 2 was adjusted by age, smoking status (for males), menopause status (for females), drinking status, exercise frequency and history of diseases. Model 3 was additionally adjusted by SBP, DBP, ALT, FPG, TC, TG, LDL-C, HDL-C, and creatinine. Model 4 was additionally adjusted by BMI based on model 3. All statistical analyses were performed with SAS 9.4 for Windows (SAS Institute, Cary, NC, USA). P values were two-tailed, and the differences were considered to be significant when P < 0.05.

**Results**

**Characteristics of participants**

The characteristics of participants by gender and hyperuricemia status are listed in Table 1. The overall prevalence of hyperuricemia was 14.8% (22.5% in men and 8.9% in women), and the average age of participants was 45.9 years. Analysis of the differences between the hyperuricemia group and non-hyperuricemia group indicated that there were significant differences in almost all indicators in both men and women, except for smoking, drinking, exercise, and history of diseases. Indicators, such as SBP, FPG, hypertension, and diabetes, were observed to have significant differences only in women, and indicators, such as LMM and regular exercise, were discovered to have significant differences only in men. The differences in the VFA-to-LMM ratio between hyperuricemia and non-hyperuricemia were shown in Fig. 2. According to this figure, there were significant differences in the VFA-to-LMM ratios not only between hyperuricemia and non-hyperuricemia but also between men and women (P < .0001). Furthermore, the subjects were divided into four groups based on the quartiles of the VFA-to-LMM ratio, and the linear trend of each indicator (Table 2) was analyzed. As the VFA-to-LMM ratio increased, most of the indicators (BMI, FPG, TG, LDL-C, SUA) witnessed a significant linear upward trend in both men and women, and only HDL-C was found to have a downward trend.

**VFA-to-LMM ratio and risk of hyperuricemia**

The association between the VFA-to-LMM ratio and hyperuricemia was explored through multiple logistic regression models, and the results were exhibited in Table 3. After adjustment by age in model 1, a strong positive association was observed between the VFA-to-LMM ratio and hyperuricemia in both men (4th vs. 1st quartile OR: 2.73; 95% CI: 1.89–3.95) and women (4th vs. 1st quartile OR: 8.25; 95% CI: 4.05–19.14), and significant linear trends were discovered in both men (P < 0.0001) and women (P < 0.0001). After additional adjustment by smoking status (for men), menopause status (for women), drinking status, exercise frequency, SBP, DBP, ALT, FPG, TC, TG, LDL-C, HDL-C, creatinine, and history of diseases in model 3, there were still significant positive association between the VFA-to-LMM ratio and hyperuricemia in both men (4th vs. 1st quartile OR: 1.60; 95% CI: 1.03–2.49) and women (4th vs. 1st quartile OR: 5.22; 95% CI: 2.44–12.56).
analyze whether the association was independent of general obesity, BMI was added as an adjustment factor in model 3. According to the results, there was still a significant positive association between the VFA-to-LMM ratio and hyperuricemia in women (4th vs. 1st quartile OR: 2.57; 95% CI: 1.06–6.77), while no association was observed in men (4th vs. 1st quartile OR: 0.97; 95% CI: 0.55–1.70).

After that, a comparison was made on the prevalence of hyperuricemia and the odds ratios of hyperuricemia between men and women according to the quartiles of the VFA-to-LMM ratio. As shown in Fig. 3, the prevalence of hyperuricemia in women was significantly lower than that in men, but the risk of hyperuricemia in women was much higher than that in men as the VFA-to-LMM ratio increased.

Subgroup analysis in women according to menopausal status
As shown in Table 4, the association between the VFA-to-LMM ratio and hyperuricemia in women with different menopausal status was demonstrated. According to

| Characteristics | Men (n = 1469) | Hyperuricemia (n = 330) | Women (n = 1924) | Hyperuricemia (n = 171) |
|-----------------|---------------|------------------------|-----------------|------------------------|
| Age, years      | 47.9 ± 15.7   | 44.4 ± 14.6            | 44.0 ± 14.5     | 54.4 ± 16.1            |
| BMI, kg/m²      | 25.4 ± 3.2    | 27.0 ± 3.5             | 22.8 ± 3.2      | 26.0 ± 3.9             |
| SBP, mmHg       | 127.0 ± 16.8  | 127.8 ± 15.4           | 117.3 ± 18.1    | 129.8 ± 19.3           |
| DBP, mmHg       | 80.2 ± 10.0   | 83.4 ± 10.0            | 75.4 ± 9.7     | 79.1 ± 11.5            |
| VFA, cm²        | 90.7 ± 32.8   | 104.9 ± 36.6           | 95.1 ± 35.4    | 129.1 ± 41.0           |
| LMM, kg         | 17.4 ± 2.2    | 18.0 ± 2.2             | 12.3 ± 1.6     | 12.5 ± 1.8             |
| ALT, units/L    | 21.6 (15.3, 31.6) | 27.3 (18.8, 45.5)     | 13.8 (10.0, 19.6) | 18.3 (13.6, 26.0) |
| FPG, mmol/L     | 5.3 (4.9, 5.9) | 5.2 (5.0, 5.7)         | 5.1 (4.8, 5.4) | 5.6 (5.1, 6.5)         |
| TC, mmol/L      | 5.0 ± 0.9     | 5.2 ± 0.9              | 5.1 ± 1.0      | 5.8 ± 1.2              |
| TG, mmol/L      | 1.3 (0.9, 1.8) | 1.7 (1.2, 2.3)         | 1.0 (0.7, 1.4) | 1.6 (1.1, 2.2)         |
| LDL-C, mmol/L   | 2.6 ± 0.5     | 2.8 ± 0.5              | 2.7 ± 0.6      | 3.1 ± 0.7              |
| HDL-C, mmol/L   | 1.3 ± 0.2     | 1.3 ± 0.2              | 1.6 ± 0.3      | 1.5 ± 0.3              |
| SUA, μmol/L     | 336.0 ± 50.3  | 468.7 ± 47.1           | 260.4 ± 45.8   | 395.3 ± 38.0           |
| Creatinine, μmol/L | 74.7 ± 10.0 | 79.8 ± 11.7           | 55.6 ± 7.7     | 61.5 ± 11.6            |
| Smoking, n (%)  | 247 (21.7)    | 69 (20.9)              | 13 (0.7)       | 0 (0.0)                |
| Drinking, n (%) | 459 (40.3)    | 129 (39.1)             | 107 (6.1)      | 5 (2.9)                |

Exercise, n (%)   
Never 285 (25.0) 95 (28.8) 0.1689 461 (26.3) 50 (29.2) 0.4057
Occasional 380 (33.4) 124 (37.6) 0.1557 733 (41.8) 63 (36.8) 0.2076
Regular 474 (41.6) 111 (33.6) 0.0091 559 (31.9) 58 (33.9) 0.5872
Hypertension, n (%)  
Diabetes, n (%)  
Cholesterol, mmol/L  
NAFLD, n (%)  
Obesity, n (%)  
History of diseases, n (%)  
Hypertension  
Diabetes  
CHD  

BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, VFA visceral fat area, LMM leg muscle mass, ALT alanine aminotransferase, FPG fasting plasma glucose, TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, SUA serum uric acid, NAFLD non-alcoholic fatty liver diseases, CHD coronary heart disease
Continuous variables are expressed as means ± standard deviation (SD) and categorical variables are expressed as percentages unless otherwise indicated
*Analysis of variance or chi-square test where appropriate
Data are expressed as medians (interquartile range)
the results, pre-menopausal women had a significantly higher risk of hyperuricemia than post-menopausal women. However, the association between the two groups was no longer significant after adjustment by BMI in model 4. It is worth noting that although the association was attenuated, the OR values of premenopausal women (4th vs. 1st quartile OR: 3.61) was still higher than that of postmenopausal women (4th vs. 1st quartile OR: 1.94), and the P value for trends was closer to 0.05 ($P = 0.1503$).

**The interaction of VFA and LMM on the risk of hyperuricemia**

In the further analysis, we divided the subjects into 16 groups according to the quartiles of VFA and LMM (the lowest quartile of VFA and the lowest quartile of LMM).

### Table 2 Characteristics of subjects according to quartiles of VFA-to-LMM ratio

| Variables of interest | Quartiles of VFA-to-LMM ratio | $P$ for Trend$^a$ |
|-----------------------|------------------------------|------------------|
|                       | Q1   | Q2   | Q3   | Q4   |                  |
| **Men**               |      |      |      |      |                  |
| No. of subjects       | 367  | 365  | 369  | 368  |                  |
| BMI, kg/m$^2$         | 22.6 ± 2.4 | 25.2 ± 2.2 | 26.1 ± 2.1 | 29.0 ± 3.1 | <.0001           |
| FPG, mmol/L           | 5.1 (4.8, 5.5) | 5.2 (4.9, 5.6) | 5.4 (5.0, 5.9) | 5.6 (5.1, 6.6) | <.0001           |
| TG, mmol/L            | 1.0 (0.7, 1.4) | 1.3 (1.0, 1.7) | 1.5 (1.1, 2.1) | 1.7 (1.2, 2.3) | <.0001           |
| LDL-C, mmol/L         | 2.5 ± 0.5 | 2.7 ± 0.5 | 2.7 ± 0.5 | 2.8 ± 0.6 | <.0001           |
| HDL-C, mmol/L         | 1.4 ± 0.3 | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.2 | <.0001           |
| Uric acid, μmol/L     | 355.6 ± 68.8 | 363.6 ± 75.2 | 366.0 ± 74.4 | 378.0 ± 77.3 | <.0001           |
| **Women**             |      |      |      |      |                  |
| No. of subjects       | 481  | 482  | 480  | 481  |                  |
| BMI, kg/m$^2$         | 20.0 ± 1.8 | 22.0 ± 2.1 | 23.9 ± 2.2 | 26.6 ± 3.1 | <.0001           |
| FPG, mmol/L           | 4.9 (4.7, 5.2) | 5.1 (4.8, 5.4) | 5.1 (4.9, 5.5) | 5.4 (5.0, 6.0) | <.0001           |
| TG, mmol/L            | 0.8 (0.6, 1.0) | 0.9 (0.7, 1.3) | 1.1 (0.8, 1.5) | 1.4 (1.0, 1.9) | <.0001           |
| LDL-C, mmol/L         | 2.5 ± 0.5 | 2.6 ± 0.5 | 2.8 ± 0.6 | 3.0 ± 0.7 | <.0001           |
| HDL-C, mmol/L         | 1.7 ± 0.3 | 1.6 ± 0.3 | 1.5 ± 0.3 | 1.5 ± 0.3 | <.0001           |
| Uric acid, μmol/L     | 248.8 ± 47.1 | 263.4 ± 52.1 | 276.1 ± 58.7 | 301.3 ± 64.8 | <.0001           |

BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, LMM leg muscle mass, TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, VFA visceral fat area

Continuous variables are expressed as means ± standard deviation (SD) and categorical variables are expressed as percentages unless otherwise indicated

$^a$P for liner trends are calculated by analysis of variance (for continuous variables) or Cochran-Armitage (for categorical variables)

$^b$Data are expressed as medians (interquartile range)
as the reference), and investigated the risk of hyperuricemia in each group after adjustment by age and gender (Fig. 4). The figure showed that the risk of hyperuricemia rose with the increasing VFA regardless of LMM, while the risk of hyperuricemia increased significantly when the LMM was in the third and highest quantiles. Remarkably, a U-shaped association was found between the risk of hyperuricemia and leg muscle mass, when VFA was in the highest quartile range, and the highest risk of hyperuricemia was discovered when VFA and LMM were both in the highest quantile (OR: 11.50; 95% CI: 4.86–31.98). The results suggested that there was an interaction between VFA and LMM, and the rising of VFA and LMM would lead to a rapid increase of hyperuricemia risks.

Discussion

In the present study, we explored the association of the VFA-to-LMM ratio with hyperuricemia. The results showed that the VFA-to-LMM ratio was positively associated with the risk of hyperuricemia in women after adjustment by age, BMI, smoking status (for males), menopause status (for females), drinking status, exercise frequency, and history of diseases (hypertension and diabetes); model 3: additionally adjusted for systolic blood pressure, diastolic blood pressure, alanine aminotransferase, fasting plasma glucose, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein cholesterol, and creatinine; model 4: adjusted for model 3 + BMI

| Quartiles of VFA-to-LMM ratio | Model 1 | Model 2 | Model 3 | Model 4 |
|-------------------------------|---------|---------|---------|---------|
| Male                          |         |         |         |         |
| Quartile 1                    | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Quartile 2                    | 1.25 (0.86, 1.82) | 1.21 (0.83, 1.77) | 0.91 (0.60, 1.36) | 0.75 (0.49, 1.15) |
| Quartile 3                    | 1.58 (1.09, 2.31) | 1.51 (1.03, 2.21) | 1.03 (0.67, 1.57) | 0.79 (0.50, 1.25) |
| Quartile 4                    | 2.73 (1.89, 3.95) | 2.49 (1.70, 3.65) | 1.60 (1.03, 2.49) | 0.97 (0.55, 1.70) |
| P for trend                   | <.0001  | <.0001  | 0.0180  | 0.9563  |
| Female                        |         |         |         |         |
| Quartile 1                    | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Quartile 2                    | 2.66 (1.23, 6.42) | 2.58 (1.19, 6.23) | 2.13 (0.96, 5.21) | 1.68 (0.75, 4.17) |
| Quartile 3                    | 5.20 (2.55, 12.10) | 4.95 (2.41, 11.54) | 3.74 (1.75, 8.95) | 2.42 (1.09, 6.01) |
| Quartile 4                    | 8.25 (4.05, 19.14) | 7.37 (3.59, 17.24) | 5.22 (2.44, 12.56) | 2.57 (1.06, 6.77) |
| P for trend                   | <.0001  | <.0001  | <.0001  | 0.0454  |

Values are ORs (95% CIs) unless otherwise indicated. VFA, visceral fat area; LMM, leg muscle mass.

Model 1: adjusted for age; model 2: adjusted for age, smoking status (for men), menopause status (for women), drinking status, exercise frequency, and history of diseases (hypertension and diabetes); model 3: additionally adjusted for systolic blood pressure, diastolic blood pressure, alanine aminotransferase, fasting plasma glucose, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein cholesterol, and creatinine; model 4: adjusted for model 3 + BMI

P values for linear trends were calculated using the median value of quartiles of VFA-to-LMM ratio

![Fig. 3](image-url) The prevalence (a) and odds ratio (b) for hyperuricemia according to quartiles of the VFA-to-LMM ratio between men and women.
However, there were still limited studies on the association between skeletal muscle mass of lower limbs and hyperuricemia. In the cross-sectional study based on 7544 adults, it revealed that serum uric acid was negatively associated with skeletal muscle mass index [15]. Similarly, Tanaka et al. [28] found that a higher SUA level was associated with reduced muscle mass in men with diabetes. Conversely, several studies unveiled that a high serum uric acid level was a protective factor of muscle function [29–31], which could counteract the excessive production of free radicals that cause muscle protein damages and eventually lead to the decline of muscle mass and strength [32].

Table 4 Subgroup analysis of the association between VFA-to-LMM ratio and hyperuricemia according to menopausal status

| Menopausal status | Model 1 a | Model 2 | Model 3 | Model 4 |
|-------------------|-----------|---------|---------|---------|
| Pre-menopausal    |           |         |         |         |
| Quartile 1        | 1.00 (ref)| 1.00 (ref)| 1.00 (ref)| 1.00 (ref)|
| Quartile 2        | 3.50 (1.06, 15.75) | 3.65 (1.10, 16.47) | 3.63 (1.04, 17.10) | 2.78 (0.79, 13.06) |
| Quartile 3        | 5.01 (1.61, 21.95) | 5.30 (1.70, 23.27) | 4.62 (1.36, 21.65) | 2.84 (0.78, 13.74) |
| Quartile 4        | 12.04 (4.21, 50.78) | 12.97 (4.50, 54.99) | 8.25 (2.52, 37.99) | 3.61 (0.90, 18.86) |
| P for trendb      | < .0001   | < .0001 | 0.0005  | 0.1503  |
| Post-menopausal   |           |         |         |         |
| Quartile 1        | 1.00 (ref)| 1.00 (ref)| 1.00 (ref)| 1.00 (ref)|
| Quartile 2        | 2.52 (1.29, 5.19) | 2.50 (1.27, 5.18) | 2.18 (1.05, 4.73) | 1.79 (0.84, 3.96) |
| Quartile 3        | 2.36 (1.20, 4.89) | 2.25 (1.14, 4.69) | 1.85 (0.88, 4.03) | 1.35 (0.61, 3.09) |
| Quartile 4        | 3.71 (1.95, 7.51) | 3.43 (1.79, 6.99) | 3.33 (1.64, 7.13) | 1.94 (0.80, 4.81) |
| P for trend       | 0.0003    | 0.0010  | 0.0029  | 0.3130  |

Values are ORs (95% CIs) unless otherwise indicated. VFA visceral fat area, LMM leg muscle mass

Model 1: adjusted for age; model 2: adjusted for age, drinking status, exercise frequency, and history of diseases (hypertension and diabetes); model 3: additionally adjusted for systolic blood pressure, diastolic blood pressure, alanine aminotransferase, fasting plasma glucose, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein cholesterol, and creatinine. model 4: adjusted for model 3 + BMI

P values for linear trends were calculated using the median value of quartiles of VFA-to-LMM ratio

Fig. 4 Age- and gender-adjusted odds ratios for hyperuricemia according to the quartiles of VFA and LMM. *The 95% confidence interval does not contain 1
In the current study, it is found that the increase of skeletal muscle mass (or the VFA-to-SMM ratio) was not associated with hyperuricemia after adjustment by BMI, but the VFA-to-LMM ratio was independently associated with the risk of hyperuricemia. The results indicated that the relative increase in skeletal muscle mass of the lower limbs has made a great contribution to the formation of hyperuricemia. There are several indirect evidences that provide partial support. For example, in a previous study, it was found that thigh circumference, a comprehensive indicator of leg muscle mass, was strongly associated with diabetes and could be used as a good predictor [33]. In another study conducted by Min et al., it was found that there was a negative association between thigh circumference and peripheral arterial diseases when thigh circumference was less than 55 cm [34]. The preceding evidence showed that the changes of leg composition are closely related to body metabolism and health status, which may promote the formation of hyperuricemia.

The underlying mechanism of the association between body composition and hyperuricemia has not been clearly elucidated. The results might be analyzed in the following three aspects: Firstly, with the accumulation of visceral fat, some pro-inflammatory cytokines, such as IL-6, IL-8, monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis factor α (TNF-α), secreted or induced by adipose tissue can lead to low-grade inflammation and oxidative stress, and further cause insulin resistance. In addition, non-esterified fatty acids (NEEAs) and resistin secreted by adipose tissue were directly related to insulin resistance [35, 36]. As the prime target of insulin, skeletal muscle was extremely important for maintaining the homeostasis of glucose and fatty acid metabolism in body. The decrease of skeletal muscle (especially leg muscle) greatly affected the metabolism of plasma fatty acid and glucose, which was further associated with insulin resistance [37]. Obviously, both visceral fat and skeletal muscle were closely associated with insulin resistance, which can lead to hyperuricemia in the following three ways: (1) IR can directly affect the reabsorption of uric acid by renal tubules and ultimately lead to the formation of hyperuricemia [38, 39]; (2) IR can indirectly cause hyperinsulinemia, which in turn provokes hyperuricemia; and (3) IR could indirectly increase the production of NADPH by promoting the lipolysis pathway, which is an important source of serum uric acid and eventually leads to hyperuricemia [40, 41]. The results showed that the increase of the VFA-to-LMM ratio led to a higher risk of hyperuricemia than the increase of VFA alone, indicating that increased LMM may play a protective role in the association, which was consistent with previous studies. Secondly, as far as we know, visceral fat accumulation is significantly associated with metabolic syndrome, while relative skeletal muscle mass was confirmed to be inversely associated with the development of metabolic syndrome [42]. Similarly, some studies have confirmed that SUA was closely related to the metabolic syndrome and may have a dual effect of cause and effect [6, 43]. It is worth noting that Kim et al. also confirmed that women with metabolic syndrome had a higher risk of hyperuricemia when they were compared with men, which was consistent with our results. Besides, some studies have shown that glucose and lipid metabolic disorder is related to the abnormal secretion of leptin, which induces oxidative stress in endothelial cells, and further leads to the increase of serum uric acid [44, 45]. Some studies have also shown that leptin, as a regulator of serum uric acid concentration, may be an intermediate factor between obesity and hyperuricemia [46]. Finally, our results showed significant gender differences, which were significant after adjustment by BMI. As we all know, there are considerable differences in both the distribution and mass of body fat and skeletal muscle between men and women due to the differences of gender hormone levels [47, 48]. Compared with women, men have a higher VFA and relatively lower SMM (or LMM), which makes the VFA-to-LMM ratio much lower than that of women. This may explain why the prevalence of hyperuricemia in men is higher than that in women, but the risk of hyperuricemia in women becomes higher as the VFA-to-LMM ratio increases. In addition, after adjustment by BMI, the association between the VFA-to-LMM ratio and hyperuricemia disappeared in men, suggesting a linear correlation between the VFA-to-LMM ratio and BMI, but for women, it is different. Therefore, the VFA-to-LMM ratio seems to have more clinical values in predicting the risk of hyperuricemia in women.

There are three advantages in the present study. First of all, as far as we know, this is the first study on the association between the VFA-to-LMM ratio and hyperuricemia. A comprehensive analysis was conducted on body composition, including VFA, LMM, and their interactions. Secondly, all measurements and statistical analysis were performed in strict accordance with the standard procedures to ensure data accuracy. Thirdly, given the significant gender differences in body composition, including VFA, LMM, and their interactions. Finally, based on the cross-sectional data, the causality of the VFA-to-LMM ratio and hyperuricemia could not be obtained, and the potential mechanism could not be further analyzed. Secondly, although confounding factors had been adjusted as many as possible, there were still factors that were not included. However, many confounders were adjusted as possible to ensure the robustness of the results.
Thirdly, due to the limitation of the sample size, further study is still needed to verify whether the association between the VFA-to-LMM ratio and hyperuricemia in subgroup analysis of women is independent of BMI.

**Perspectives and significance**

According to the results, the metabolism of uric acid can be indirectly reflected in body shape, and the indicator studied in this paper can well predict the risk of hyperuricemia in women. The findings facilitated the prediction of high-risk groups of hyperuricemia by simple body composition examination or even apparent body shape. The results of subgroup analysis in the female population suggested that more attention should be paid to the changes of the VFA and LMM in premenopausal women. In addition, the results provided potential values for the prevention of hyperuricemia.

**Conclusion**

According to the research results, the VFA-to-LMM ratio is positively associated with the risk of hyperuricemia in women after adjustment by confounding factors, and women are more sensitive than men to the risk of hyperuricemia caused by changes in body composition. In addition, pre-menopausal women have a higher risk to suffer from hyperuricemia than post-menopausal women with the increase of the VFA-to-LMM ratio. However, well-controlled prospective studies are needed to further confirm the causality between the VFA-to-LMM ratio and hyperuricemia.

**Abbreviations**

ALT: Alanine aminotransferase; BMI: Body mass index; CI: Confidence interval; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; HDL-C: High-density lipoprotein cholesterol; IR: Insulin resistance; LDL-C: Low-density lipoprotein cholesterol; LMM: Leg muscle mass; NAFLD: Non-alcoholic fatty liver disease; OR: Odds ratio; SMM: Skeletal muscle mass; SUA: Serum uric acid; SBP: Systolic blood pressure; TC: Total cholesterol; TG: Triglycerides; VFA: Visceral fat area

**Acknowledgements**

We gratefully acknowledge all the participants of the study, Tianjin Union Medical Center-Health Management Department and Nankai University Affiliated Hospital and for the possibility to perform the study. All data generated during this study can be freely obtained with the permission of corresponding authors.

**Authors’ contributions**

CJ and JNL contributed to the concept and design of the study; WRU and XHW contributed to the design of analysis, statistical analysis, and manuscript preparation; CJL, WRJ, XHW, YPJ, MYZ, and YXS contributed to coordination of the fieldwork, data collection and management, and interpretation of results and revision of manuscript drafts. All authors were involved in the interpretation of the results and the revision of the manuscript and approved the submitted version of the manuscript.

**Funding**

This work was partially supported by Grants from Natural Science Foundation of Tianjin (19JCZDJC36100 to CJL and 18ZXDBSY22120 to JNL) and National Key R&D Program of China (2016YFC0900560, 2016YFC0900604 to MYZ).

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Tianjin Union Medical Center, Nankai University affiliated hospital. All participants were informed about the study objectives and examination procedures in detail, and were asked to sign the informed consent form before they were enrolled.

**Consent for publication**

Not applicable.

**Competing interests**

All authors have no conflicts of interest to disclose.

**Author details**

1. Department of Endocrinology, Health Management Center, Tianjin Union Medical Center, Nankai University Affiliated Hospital, 190 of Jeyuan Road, Hongqiao District, Tianjin 300121, China. 2. College of Medicine, Nankai University, Tianjin, China. 3. Orofacial Pain and TMJ Disorders, Eastman Institute for Oral Health, University of Rochester, New York, NY, USA.

**Received:** 29 September 2020 **Accepted:** 17 January 2021

**Published online:** 29 January 2021

**References**

1. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. Arthritis Rheum. 2019;71(6):991–9. https://doi.org/10.1002/art.40807.
2. Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820. https://doi.org/10.1155/2015/762820.
3. Yang WX, Ma Y, Hou YL, Wang YB, You CG. Prevalence of hyperuricemia and its correlation with serum lipids and blood glucose in physical examination population in 2015-2018: a retrospective study. Clin Lab. 2019; 65(8):1. https://doi.org/10.7754/ClinLab.2019.190338.
4. Simao AN, Lozovoy MA, Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opin Ther Targets. 2012;16(12):1175–87. https://doi.org/10.1517/14728222.2012.723694.
5. Yu TY, Jee JH, Bae JC, Jin SM, Baek JH, Lee MK, et al. Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition. Metabolism. 2016;65(4):332–40. https://doi.org/10.1016/j.metabol.2015.11.003.
6. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab. 2004;1(1):10. https://doi.org/10.1186/1473-7771-1-10.
7. Kuwabara M, Kuwabara R, Hisatome I, Niwai K, Roncal-Jimenez CA, Bjornstad P, et al. “Metabolically healthy” obesity and hyperuricemia increase risk for hypertension and diabetes: 5-year Japanese cohort study. Obesity (Silver Spring). 2017;25(11):1997–2008. https://doi.org/10.1002/oby.22000.
8. Sandra S, Lesmana CRA, Purnamasari D, Kurniawan J, Gani RA. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: lesion learnt from tertiary referral center. Diabetol Metab Syndr. 2019;11(1):424–8. https://doi.org/10.1016/j.dsx.2018.10.001.
9. Xie Y, Xu P, Liu K, Lin S, Wang M, Tian T, et al. Hyperuricemia and gout are associated with cancer incidence and mortality: a meta-analysis based on cohort studies. J Cell Physiol. 2019;234(8):14364–76. https://doi.org/10.1002/jcp.28138.
10. Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population impact attributable to modifiable risk factors for hyperuricemia. Arthritis Rheum. 2020;72(1):157–65. https://doi.org/10.1002/art.41067.
11. Han T, Meng X, Shan R, Zi T, Li Y, Ma H, et al. Temporal relationship between hyperuricemia and obesity, and its association with future risk of
type 2 diabetes. Int J Obes. 2018;42(7):1336–44. https://doi.org/10.1038/s41366-018-0074-5.

12. Yamada A, Sato KK, Kinuha S, Uehara S, Endo G, Hikita Y, et al. Association of visceral fat and Liver fat with Hyperuricemia. Arthritis Care Res. 2016;68(4):553–61. https://doi.org/10.1002/art.27292.

13. Matsushita F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47(8):929–33. https://doi.org/10.1016/s0026-0495(98)09346-8.

14. Dong H, Xu Y, Zhang X, Tian S. Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. Sci Rep. 2017;7(1):18022. https://doi.org/10.1038/s41598-017-09455-z.

15. Beavers KM, Beavers DP, Serra MC, Bowden RG, Wilson RL. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: findings from NHANES III. Nutr Health Aging. 2009;9(3):177–82. https://doi.org/10.1016/j.shaw.2009.09.054-5.

16. Alvim RQ, Siqueira JT, Zaniquelli D, Dutra DM, Oliosa PR, Mill JG. Influence of muscle mass on the serum uric acid levels in children and adolescents: Nutr Metab Cardiovasc Dis. 2020;30(2):300–5. https://doi.org/10.1016/j.numecd.2019.08.019.

17. Heshka S, Ruggiero A, Bray GA, Foreyt J, Kahn SE, Lewis CE, et al. Altered body composition in type 2 diabetes mellitus. Int J Obes. 2003;27(5):780–7. https://doi.org/10.1038/sj.ijo.0803802.

18. Jun DW, Han JH, Kim SH, Jang EC, Kim NI, Lee JS, et al. Association between low thigh fat and non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2008;23(6):888–93. https://doi.org/10.1111/j.1440-1746.2008.05330.x.

19. Park JS, Cho MH, Ahn CW, Kim KR, Huh KB. The association of insulin resistance and carotid atherosclerosis with thigh and calf circumference in patients with type 2 diabetes. Cardiovasc Diabetol. 2012;11:62. https://doi.org/10.1186/1475-2840-11-62.

20. Snijder MB, Dekker JM, Visser M, Bouten LM, Stehouwer CD, Kostense PJ, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn study. Am J Clin Nutr. 2003;77(5):1192–7. https://doi.org/10.1093/ajcn/77.5.1192.

21. Snijder MB, Visser M, Dekker JM, Goodpaster BH, Harris TB, Kitchinsey SB, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The health ABC study. Metabolism. 2005;54(8):2840–11. https://doi.org/10.1016/j.metabol.2005.06.006.

22. Lima WG, Martini-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;161:167–23. https://doi.org/10.1016/j.biochi.2015.06.025.

23. Jao X, Zhang G, Li G, Yin X, Shen X. Analysis on correlations of serum uric acid with glucose and lipid metabolism and renal function of patients with newly-diagnosed and long-term type 2 diabetes mellitus. Panminerva Med. 2019;Pub ahead of print. https://doi.org/10.17336/pkm.0080.116.03635-8.

24. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1–20. https://doi.org/10.23736/S0031-0808.19.03635-8.

25. Jiao X, Zhang G, Li G, Yin X, Shen X. Analysis on correlations of serum uric acid with glucose and lipid metabolism and renal function of patients with newly-diagnosed and long-term type 2 diabetes mellitus. Panminerva Med. 2019;Pub ahead of print. https://doi.org/10.17336/pkm.0080.116.03635-8.

26. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775–7. https://doi.org/10.1111/j.1440-1746.2007.05002.x.

27. Joint committee for guideline r. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1–29. https://doi.org/10.10010/j.issn.1671-5411.2018.01.011.

28. Huang X, Jiang X, Wang L, Chen L, Wu Y, Gao P, et al. Visceral adipose accumulation increased the risk of hyperuricemia among middle-aged and elderly adults: a population-based study. J Transl Med. 2019;17(1):341. https://doi.org/10.1186/s12967-019-2074-1.

29. Takahashi S, Yamamoto T, Tsutsuura Z, Morikawa Y, Yamaoka J, Higashino K. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism. 1997;46(10):1162–5. https://doi.org/10.1016/s0026-0495(97)00210-9.

30. Tanaka KI, Kanazawa I, Notsu M, Sugimoto T. Higher serum uric acid is a risk factor of reduced muscle mass in men with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2018;Pub ahead of print. https://doi.org/10.1055/s-0038-1642295.

31. Molino-Lova R, Sofi F, Pasquini G, Vannetti F, Del Ry S, Vassalle C, et al. Higher uric acid serum levels are associated with better muscle function in the oldest old: results from the Mugello study. Eur J Intern Med. 2017;41:39–43. https://doi.org/10.1016/j.ejim.2017.03.014.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.